What are the side effects of Opsynvi (Macitentan and Tadalafil)?
Opsynvi (Macitentan and Tadalafil) is a combination of Macitentan and Tadalafil, indicated for the chronic treatment of adults with pulmonary arterial hypertension (PAH, World Health Organization group I and World Health Organization Functional Classification [FC] II-III). On a single-agent basis, macitentan reduced the risk of clinical worsening events and hospitalization, and tadalafil improved exercise capacity.
Pulmonary hypertension is a rare progressive life-threatening vascular disease characterized by narrowing of small pulmonary arteries and increased blood pressure in the pulmonary circulation, ultimately leading to right heart failure. People with pulmonary hypertension often bear the burden of taking multiple medications every day. Because coadministration of macitentan and Tadalafil is commonly used for the initial treatment of pulmonary hypertension, the launch of a single tablet combining the two may help bridge the gap between clinical guidelines and daily clinical practice.
In clinical studies of Opsynvi, common adverse reactions in patients included edema/fluid retention, anemia, and headache/migraine. These side effects may affect patient comfort and quality of life. In addition, the most common adverse reactions leading to discontinuation were anemia and hemoglobin reduction, as well as peripheral edema and peripheral swelling. Warnings and precautions related to Opsynvi include hepatotoxicity, hypotension, decreased hemoglobin, worsening of pulmonary veno-occlusive disease, vision loss, hearing impairment, fluid retention, decreased sperm count, and prolonged erection.
Opsynvi side effects are adverse reactions or discomfort that may occur while using this drug. These side effects include not only some serious warnings and precautions, but also some common adverse reactions. During the period of using Opsynvi, patients should cooperate closely, follow the doctor's recommendations, and conduct relevant examinations and monitoring regularly to ensure safe and effective treatment, and promptly report any abnormal reactions to the doctor.
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)